CBT
VRTX icon

Capital Bank & Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Bank & Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-89,680
Closed -$18.1M – 188
2021
Q2 		$18.1M Buy
89,680
+1,033
+1% +$216K 0.21% 104
2021
Q1 		$19M Buy
88,647
+1,716
+2% +$377K 0.23% 104
2020
Q4 		$20.5M Sell
86,931
-34,969
-29% -$8.02M 0.25% 96
2020
Q3 		$33.2M Buy
121,900
+1,114
+0.9% +$307K 0.45% 67
2020
Q2 		$35.1M Buy
120,786
+330
+0.3% +$89.5K 0.51% 56
2020
Q1 		$28.7M Buy
120,456
+11,685
+11% +$2.68M 0.48% 58
2019
Q4 		$23.8M Buy
108,771
+108,521
+43,408% +$22M 0.31% 83
2019
Q3 		$42K Sell
250
-18
-7% -$3.18K ﹤0.01% 451
2019
Q2 		$49K Buy
268
+7
+3% +$1.22K ﹤0.01% 429
2019
Q1 		$48K Sell
261
-108
-29% -$19.9K ﹤0.01% 409
2018
Q4 		$61K Buy
369
+203
+122% +$35.2K ﹤0.01% 396
2018
Q3 		$32K Buy
166
+115
+225% +$20.5K ﹤0.01% 519
2018
Q2 		$9K Hold
51
– – ﹤0.01% 545
2018
Q1 		$8K Hold
51
– – ﹤0.01% 538
2017
Q4 		$8K Buy
+51
New +$7.55K ﹤0.01% 570

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Bank & Trust's VRTX Position: Q3 2021 in Review

Capital Bank & Trust sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 89,680 shares — an estimated $18.1M sold.

Capital Bank & Trust first reported a position in VRTX in Q4 2017 and held it in 15 quarters. The position peaked at $35.1M in Q2 2020. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Capital Bank & Trust reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Capital Bank & Trust sold 89,680 Vertex Pharmaceuticals shares in Q3 2021, an estimated $18.1M.
  • Capital Bank & Trust first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 15 quarters.
  • Capital Bank & Trust's Vertex Pharmaceuticals position peaked at $35.1M in Q2 2020.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Capital Bank & Trust's 13F filing for Q3 2021, filed 15 Nov 2021.